RECRUITING

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.

Official Title

AHPBA Pancreatic Irreversible Electroporation (IRE) Registry for Pancreatic Cancer

Quick Facts

Study Start:2016-01
Study Completion:2030-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02674100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult patients (greater than 18 years of age) diagnosed with pancreatic cancer that are eligible for soft tissue ablation per the treating physician.
  1. * Have a cardiac pacemaker or ICD implant
  2. * Non-removable implants with metal parts near target lesion
  3. * Myocardial infarction within 3 months prior to enrollment
  4. * Not suitable for general endotracheal anesthesia

Contacts and Locations

Study Contact

Robert Martin, MD, PhD
CONTACT
502-629-3355
robert.martin@louisville.edu

Principal Investigator

Robert Martin, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Louisville

Study Locations (Sites)

University of Alabama Birmingham
Birmingham, Alabama, 35233
United States
University of California San Diego
San Diego, California, 92093
United States
University of Colorado
Denver, Colorado, 80309
United States
University of South Florida
Tampa, Florida, 33620
United States
Augusta University
Augusta, Georgia, 30912
United States
University of Louisville
Louisville, Kentucky, 40202
United States
Johns Hopkins Hospital
Baltimore, Maryland, 21218
United States
Atlantic Health
Millburn, New Jersey, 07041
United States
Northwell Health Cancer Institute
Lake Success, New York, 11042
United States
Gibbs Cancer Research, Spartanburg Regional Healthcare System
Spartanburg, South Carolina, 29303
United States
Methodist Digestive Institute
Dallas, Texas, 75203
United States

Collaborators and Investigators

Sponsor: University of Louisville

  • Robert Martin, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Louisville

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-01
Study Completion Date2030-01

Study Record Updates

Study Start Date2016-01
Study Completion Date2030-01

Terms related to this study

Additional Relevant MeSH Terms

  • Pancreatic Cancer